This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
The FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis, a disease that can require repeated surgical removal of growths in the airway. The approval is intended to reduce the frequency of those surgeries, according to MedPage Today.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections
The approval gives eligible adults a new treatment option aimed at reducing repeat surgeries. The article does not provide details on availability, cost or how much the treatment reduces procedures.
No further regulatory steps or dates are specified in the report.
When and how the treatment becomes available to patients.
Further information on its effectiveness and use after accelerated approval.